+ A
A -
Tribune News Network
Doha
The Ministry of Public Health’s proactive approach to secure COVID-19 vaccine from various sources has proven effective, Dr Abdullatif Al Khal, the Chair of the National Health Strategic Group on COVID-19, has said.
He was referring to Qatar’s agreement with Pfizer and Moderna, the two frontrunners in the global race to develop an effective COVID-19 vaccine.
Pfizer on Wednesday announced that a completed study of its experimental COVID-19 vaccine showed it is 95 percent effective. On Monday, Moderna said its own vaccine was 94.5 percent effective, according to a preliminary analysis.
Dr Khal said Qatar’s Ministry of Public Health signed a deal with Moderna in mid-October to purchase its COVID-19 vaccine as soon as it was approved and proved its suitability for use on the global level.
Qatar has also signed a similar agreement with Pfizer and its partnering firm BioNtech, he added.
Dr Khal said it was promising that Qatar had agreements with the two companies, whose candidate vaccines achieved high rates of effectiveness in clinical trials against COVID-19.
Doha
The Ministry of Public Health’s proactive approach to secure COVID-19 vaccine from various sources has proven effective, Dr Abdullatif Al Khal, the Chair of the National Health Strategic Group on COVID-19, has said.
He was referring to Qatar’s agreement with Pfizer and Moderna, the two frontrunners in the global race to develop an effective COVID-19 vaccine.
Pfizer on Wednesday announced that a completed study of its experimental COVID-19 vaccine showed it is 95 percent effective. On Monday, Moderna said its own vaccine was 94.5 percent effective, according to a preliminary analysis.
Dr Khal said Qatar’s Ministry of Public Health signed a deal with Moderna in mid-October to purchase its COVID-19 vaccine as soon as it was approved and proved its suitability for use on the global level.
Qatar has also signed a similar agreement with Pfizer and its partnering firm BioNtech, he added.
Dr Khal said it was promising that Qatar had agreements with the two companies, whose candidate vaccines achieved high rates of effectiveness in clinical trials against COVID-19.
